Infections due to carbapenem-resistant gram-negative bacteria such as Enterobacteriaceae (new taxonomy: Enterobacterales) and *Pseudomonas aeruginosa* pose a serious threat to global public health due to increased mortality, hospital length of stay, and cost compared with carbapenem-susceptible infections \[[@CIT0001]\]. Potential treatment options for carbapenem-resistant infections include polymyxins (polymyxin B and colistin \[polymyxin E\]), tigecycline, aminoglycosides, ceftazidime-avibactam, and meropenem-vaborbactam \[[@CIT0006]\]; however, polymyxins, including colistin, are associated with toxicities and other important safety concerns that can further complicate the management of patients with drug-resistant bacterial infections who are medically complex (eg, patients with multiple comorbidities, patients at risk of renal injury or who have preexisting renal insufficiency, and/or patients taking concomitant nephrotoxic medications) \[[@CIT0011]\].

Nephrotoxicity is commonly associated with polymyxin-based therapy \[[@CIT0012], [@CIT0013]\]. The reported rates of nephrotoxicity increase with higher concentrations or doses and longer durations of therapy \[[@CIT0011], [@CIT0014]\]. Current guidelines recommend that polymyxins be used in combination with other agents to maximize the clinical effect \[[@CIT0008], [@CIT0017], [@CIT0018]\]. However, rates of nephrotoxicity are high with colistin and colistin-based combination therapies, ranging from 12% to 29% in some studies \[[@CIT0012], [@CIT0016], [@CIT0019], [@CIT0020]\]. Further complicating the clinical management of these serious bacterial infections is that nephrotoxicity with polymyxins (especially colistin) can occur soon after initiation of treatment \[[@CIT0021], [@CIT0022]\].

Recently, there has been an increased focus on the development of novel therapies that can address increased incidences of antibacterial-resistant infections and offer improved safety over older drugs such as colistin. Relebactam (REL) is a β-lactamase inhibitor active against Ambler Class A and C enzymes that can restore imipenem activity against many imipenem-nonsusceptible strains of gram-negative bacteria \[[@CIT0009], [@CIT0010]\]. In the phase 3 RESTORE-IMI 1 trial (NCT02452047), the combination of imipenem/cilastatin (IMI) with relebactam (IMI/REL) had comparable efficacy to colistin plus IMI in the primary end point of favorable overall response and was better tolerated, including a lower incidence of protocol-defined treatment-emergent nephrotoxicity (10.3% \[3/29\] vs 56.3% \[9/16\]; *P *= .002) \[[@CIT0023]\].

To date, no single biomarker or set definition of drug-induced nephrotoxicity has been established for use in drug development trials \[[@CIT0024], [@CIT0025]\]. Here we present an additional exploratory, post hoc analysis of renal safety data from the phase 3 RESTORE-IMI 1 trial, including an evaluation of nephrotoxicity using 2 acute kidney injury (AKI) assessment criteria commonly cited in the literature (Kidney Disease Improving Global Outcomes \[KDIGO\] and Risk, Injury, Failure, Loss, and End-stage Kidney Disease \[RIFLE\]) ([Table 1](#T1){ref-type="table"}) \[[@CIT0026], [@CIT0027]\].

###### 

Criteria for Assessment of Treatment-Emergent Nephrotoxicity

  Protocol-Defined Criteria^a^                    
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------
  Normal (serum Cr \<1.2 mg/dL)                   Doubling of Cr up to \>1.2 mg/dL OR ≥50% reduction in CrCl
  Preexisting dysfunction (serum Cr ≥1.2 mg/dL)   Increases in Cr ≥1 mg/dL OR ≥20% reduction in CrCl OR Initiation of renal replacement therapy
  KDIGO Criteria^b^                               
  Stage^c^                                        Serum Cr
  1                                               1.5--1.9 times baseline OR ≥0.3 mg/dL (≥26.5 µmol/L) increase
  2                                               2.0--2.9 times baseline
  3                                               3.0 times baseline OR Increase ≥4.0 mg/dL (≥353.6 µmol/L) OR Initiation of renal replacement therapy
  RIFLE Criteria                                  
  Classification^c,d^                             GFR Criteria
  Risk                                            Increased serum Cr × 1.5 OR GFR decrease \>25%
  Injury                                          Increased serum Cr × 2 OR GFR decrease \>50%
  Failure                                         Increased serum Cr × 3 OR GFR decrease 75% OR Serum creatinine ≥4 mg/dL (acute rise ≥0.5 mg/dL)

Abbreviations: AKI, acute kidney injury; Cr, creatinine; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney Disease.

^a^Criteria assessed a priori.

^b^Criteria assessed retrospectively.

^c^If a participant met criteria for \>1 AKI stage/classification, the participant was included only once, in the "worst-case" stage/classification.

^d^Loss of kidney function (\>4 weeks) and end-stage kidney disease (\>3 months) classifications were not included due to the study duration being less than the defined timelines.

METHODS {#s1}
=======

Study Design and Participants {#s2}
-----------------------------

RESTORE-IMI-1 (Protocol MK-7655A-013) was a phase 3, randomized, active comparator--controlled, double-blind study to evaluate the efficacy and safety of IMI/REL compared with colistin plus IMI in participants enrolled at 16 sites in 11 countries between October 2015 and September 2017. The study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. The approach of Merck & Co., Inc., to the conduct of clinical trials is in accordance with ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and the applicable regulatory requirement(s). Written patient consent was obtained before screening. The full methodology was published previously \[[@CIT0023]\].

Briefly, eligible participants were aged ≥18 years and required hospitalization and treatment with intravenous (IV) antibiotics for serious gram-negative infections (complicated intra-abdominal infection \[cIAI\], complicated urinary tract infection \[cUTI\], hospital-acquired bacterial pneumonia \[HABP\], or ventilator-associated bacterial pneumonia \[VABP\]) caused by pathogens confirmed to be imipenem-nonsusceptible, but susceptible to imipenem/relebactam and colistin. Participants were excluded if they had an APACHE II score \>30, creatinine clearance (CrCl) \<15 mL/min, or if they required hemodialysis or peritoneal dialysis.

Eligible participants were randomized (stratified by infection type) 2:1 to IV IMI/REL (500 mg/250 mg every 6 hours; IMI dose includes 500 mg imipenem and 500 mg cilastatin) plus placebo or IV colistin (as colistimethate sodium; loading dose to achieve 300 mg colistin base activity \[CBA\], followed by maintenance doses every 12 hours based on CrCl up to 150 mg CBA) + IMI (500 mg every 6 hours) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Doses for all 3 study drugs were adjusted based on renal function ([Supplementary Table 1](#sup3){ref-type="supplementary-material"}), and the duration of therapy was determined by infection type and did not exceed 21 days.

Measurements and Criteria for AKI {#s3}
---------------------------------

Blood for laboratory safety tests (hematology and chemistry) was collected for analysis at a central laboratory at randomization (day 1) before administration of the first dose of IV therapy, on day 3, and every 3 days thereafter until the end of therapy (EOT), and then at the following visits: EOT, early follow-up (5--9 days after EOT), day 28 postrandomization, and safety follow-up (14 days after EOT) ([Supplementary Figure 2](#sup2){ref-type="supplementary-material"}). Urine was collected for analysis on day 1 and at EOT.

Data contributing to the assessment of nephrotoxicity were collected from both central and local laboratories (local collection was performed as needed to ensure timely patient management). Treatment-emergent nephrotoxicity was assessed a priori by protocol-defined criteria and by guideline-based definitions of AKI (KDIGO and RIFLE), which were assessed retrospectively ([Table 1](#T1){ref-type="table"}) \[[@CIT0020], [@CIT0027]\]. Information on renal adverse events (AEs) and renal AEs leading to discontinuation was collected from the first dose of IV study therapy through 14 days after EOT. AEs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA; version 20.0). Renal AEs that may be clinically relevant indicators of potential renal injury were derived from the renal and urinary disorders and investigations system organ classes. The relationship of any AE to study medication was determined by the investigator assessment during IV therapy through safety follow-up.

Statistical Analysis {#s4}
--------------------

The safety population was used for all safety assessments and was defined as all randomized participants who received ≥1 dose of IV study treatment according to the actual treatment received. Descriptive statistics were used to summarize baseline demographics, AEs, and treatment-emergent nephrotoxicity. A planned comparison of treatment-emergent nephrotoxicity rates based on protocol-defined criteria was performed using 2-sided *P* values obtained using the Fisher exact test. Analyses of additional end points were conducted to further assess and confirm the prespecified nephrotoxicity end point. Although these new end points were not prespecified, the 2-sided *P* values from the Fisher exact test have been included here for consistency. As the latter comparisons were not preplanned, these *P* values are simply to provide additional evidence in support of the preplanned end point.

RESULTS {#s5}
=======

A total of 47 participants were in the safety population, including 31 participants treated with IMI/REL and 16 participants treated with colistin plus IMI. The study population in each treatment group was balanced with respect to sex, weight, APACHE II score, primary diagnosis, and CrCl ([Table 2](#T2){ref-type="table"}). The majority of participants in the IMI/REL and colistin plus IMI treatment groups had a primary diagnosis of cUTI, followed by HABP/VABP and cIAI. At baseline, the majority of participants (74.5%) had normal renal function or mild renal impairment (ie, CrCl ≥ 60 mL/min), as calculated by the Cockcroft-Gault equation.

###### 

Baseline Demographics and Clinical Characteristics (Safety Population)

                                        IMI/REL (n = 31)   Colistin + IMI (n = 16)   Total (n = 47)
  ------------------------------------- ------------------ ------------------------- ------------------
  Sex, No. (%)                                                                       
   Male                                 20 (64.5)          10 (62.5)                 30 (63.8)
   Female                               11 (35.5)          6 (37.5)                  17 (36.2)
  Age                                                                                
   \<65 y, No. (%)                      19 (61.3)          7 (43.8)                  26 (55.3)
   ≥65 y, No. (%)                       12 (38.7)          9 (56.3)                  21 (44.7)
   Median (range)                       59 (19--77)        66 (22--80)               59 (19--80)
  Weight, kg                                                                         
   Median (range)                       76 (49.0--140.0)   73.5 (52.8--117.0)        75.8 (49--140.0)
  APACHE II score, No. (%)                                                           
   ≤15                                  22 (71.0)          12 (75.0)                 34 (72.3)
   \>15                                 9 (29.0)           4 (25.0)                  13 (27.7)
  Primary diagnosis, No. (%)                                                         
   HABP                                 1 (3.2)            1 (6.3)                   2 (4.3)
   VABP                                 9 (29.0)           5 (31.3)                  14 (29.8)
   cIAI                                 5 (16.1)           3 (18.8)                  8 (17.0)
   cUTI (urinary tract abnormalities)   9 (29.0)           3 (18.8)                  12 (25.5)
   cUTI (acute pyelonephritis)          7 (22.6)           4 (25.0)                  11 (23.4)
  CrCl, No. (%)                                                                      
   ≥90 mL/min                           10 (32.3)          6 (37.5)                  16 (34.0)
   \<90 to ≥60 mL/min                   14 (45.2)          5 (31.3)                  19 (40.4)
   \<60 to ≥30 mL/min                   5 (16.1)           3 (18.8)                  8 (17.0)
   \<30 to ≥15 mL/min                   1 (3.2)            2 (12.5)                  3 (6.4)
   Not available                        1 (3.2)            0 (0.0)                   1 (2.1)

Abbreviations: APACHE II, Acute Physiologic Assessment and Chronic Health Evaluation II; cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HABP, hospital-acquired bacterial pneumonia; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; VABP, ventilator-associated bacterial pneumonia.

Of the 47 participants in the safety population, 45 had complete data for assessment of nephrotoxicity; 2 participants in the IMI/REL group had missing creatinine values and were excluded. As was reported previously, a significantly smaller percentage of participants in the IMI/REL group than in the colistin plus IMI group experienced protocol-defined treatment-emergent nephrotoxicity (10.3% \[3/29\] vs 56.3% \[9/16\]; treatment difference, --45.9%; 95% confidence interval, --69.1% to --18.4%; *P *= .002) ([Figure 1](#F1){ref-type="fig"}) \[[@CIT0023]\]. A post hoc review of the timing of protocol-defined nephrotoxicity onset shows a wide range of onset, with no discernible pattern related to primary diagnosis or treatment arm ([Figure 2](#F2){ref-type="fig"}). For IMI/REL, the first occurrence of protocol-defined nephrotoxicity occurred as early as day 3 and as late as day 22. In the colistin plus IMI group, the first occurrence of nephrotoxicity occurred as early as day 2 and as late as day 19. The magnitude of CrCl reduction at any point in participants experiencing protocol-defined nephrotoxicity ranged from 20.1% to 54.2% in IMI/REL-treated participants and 0.3% to 86.8% in participants treated with colistin plus IMI.

![Participants with protocol-defined nephrotoxicity or AKI by KDIGO or RIFLE criteria. If the patient met criteria for \>1 AKI stage, they were only included once, in the worst-case stage. ^a^Two participants in the IMI/REL group with missing creatinine values were excluded from the nephrotoxicity and AKI evaluations.Abbreviations: AKI, acute kidney injury; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; KDIGO, Kidney Disease: Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney Disease.](ofaa054f0001){#F1}

![Time to nephrotoxicity event. Abbreviations: cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HABP, hospital-acquired bacterial pneumonia; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; VABP, ventilator-associated bacterial pneumonia.](ofaa054f0002){#F2}

When evaluated according to KDIGO criteria, the proportion of patients with AKI (stage 1--3) was significantly lower for the IMI/REL group compared with the colistin plus IMI group (20.7% \[6/29\] vs 81.3% \[13/16\]; treatment difference, --60.6%; *P *\< .001) ([Figure 1](#F1){ref-type="fig"}). No participants in the IMI/REL group were classified as stage 3 AKI compared with 31.3% of participants in the colistin plus IMI group). The proportion of patients with stage 1 and 2 AKI was also smaller in the IMI/REL group compared with colistin plus IMI. Assessment according to RIFLE criteria found that nephrotoxicity was significantly lower for the IMI/REL group compared with the colistin plus IMI group (17.2% \[5/29\] vs 75.0% \[12/16\]; treatment difference, --57.8%; *P* \< .001). No participants in the IMI/REL group experienced renal failure compared with 25.0% of participants in the colistin plus IMI group. In addition, a lower proportion of patients in the IMI/REL group experienced risk or injury per RIFLE criteria compared with colistin plus IMI.

By MedDRA terms, a total of 10 participants experienced ≥1 renal AE: 4 in the IMI/REL group (12.9%) and 6 in the colistin plus IMI group (37.5%) ([Table 3](#T3){ref-type="table"}). The most common renal AE was "blood creatinine increased," occurring with greater frequency in the colistin plus IMI group (IMI/REL 0% vs colistin plus IMI 25.0%). There was 1 AE of AKI and 1 AE of renal failure observed in 2 patients in the IMI/REL group. There were no drug-related renal AEs leading to discontinuation of treatment in the IMI/REL group, but there were 2 in the colistin plus IMI group (1 patient each due to "blood creatinine decreased" and "CrCl decreased").

###### 

Renal AEs^a^ (Safety Population)

                                                                      IMI/REL   Colistin + IMI          
  ------------------------------------------------------------------- --------- ---------------- ------ ------
  Renal AEs                                                           n/m       \%               n/m    \%
   Patients with ≥1 renal AE                                          4/31      12.9             6/16   37.5
    Blood creatinine increased                                        0/31      0                4/16   25.0
    Blood urea increased                                              0/31      0                1/16   6.3
    Creatinine clearance decreased                                    2/31      6.5              2/16   12.5
    Glomerular filtration rate decreased                              0/31      0                1/16   6.3
    Acute kidney injury                                               1/31      3.2              0/16   0
    Renal failure                                                     1/31      3.2              0/16   0
  Drug-related renal AEs leading to discontinuation of treatment^b^   n/m       \%               n/m    \%
   Blood Cr increased                                                 0/31      0                1/16   6.3
   CrCl decreased                                                     0/31      0                1/16   6.3

Abbreviations: AE, adverse event; Cr, creatinine; CrCl, creatinine clearance; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; n/m, number of participants with the observation of interest/number of evaluable participants.

^a^AEs were classified according to the Medical Dictionary for Regulatory Activities, version 20.0.

^b^Based on investigator assessment.

Key characteristics for the 10 participants who experienced ≥1 renal AE are shown in [Supplementary Table 2](#sup3){ref-type="supplementary-material"}. Treatment-emergent renal AEs occurred in participants of a broad age range (40 to 80 years), and time to onset varied widely in both treatment groups (IMI/REL: 3 to 19 days; colistin + IMI: 2 to 19 days). There was no discernible pattern to potential factors that may have contributed to renal AEs. Most participants, but not all, had a history of renal impairment, AKI, or chronic kidney disease or received a potentially nephrotoxic medication (eg, colistin, vancomycin, aminoglycoside) within 7 days of starting study medication.

Two patients in the colistin plus IMI treatment arm required initiation of dialysis during the study period, which was initiated on day 3. One patient died the following day due to cardiac arrest, which was deemed unrelated to the study medication. The other patient received dialysis until day 8, when the patient died from hypoxic brain injury. This death was also deemed unrelated to the study medication. No patients who received IMI/REL required dialysis during therapy.

DISCUSSION {#s6}
==========

In the phase 3 RESTORE-IMI 1 study, IMI/REL was as effective as colistin plus IMI in several outcome measures (overall response, clinical response, and 28-day mortality) but was better tolerated, including a significantly lower incidence of protocol-defined nephrotoxicity \[[@CIT0023]\]. Our additional analyses of safety data from that trial further supported the conclusion of improved renal safety with IMI/REL compared with colistin-based therapy \[[@CIT0023]\]. Evaluation of renal safety data using 2 widely accepted assessment criteria demonstrated that no participants who received IMI/REL experienced stage 3 AKI by KDIGO guidelines or failure by RIFLE criteria and that IMI/REL resulted in fewer incidents of AKI in the less severe strata for both KDIGO and RIFLE. Overall, nephrotoxicity rates determined by KDIGO guidelines and RIFLE criteria were higher in the colistin plus IMI group. Furthermore, renal AEs, based on MedDRA terms, were infrequent in the IMI/REL treatment group, and no IMI/REL-treated participants discontinued treatment due to drug-related renal AEs. Capturing AEs by investigator assessment is subjective and may not be supported with laboratory data; however, the overall trends observed using investigator assessment generally aligned with improved renal safety.

A review of relevant characteristics of the 10 patients who experienced renal AEs showed no discernible pattern of potential contributing factors. The majority (n = 8) of these patient cases were medically complex (serious infections with multiple comorbidities including prior history of renal impairment and/or prior use of nephrotoxic medications), but there were also 2 participants who had no history of renal impairment and/or no prior use of nephrotoxic medications who developed renal AEs. This underscores the importance of considering the renal safety profile of antibacterial agents selected for management of the full spectrum of patient cases.

Nephrotoxicity rates reported in the literature for colistin-based therapy vary widely from 0% to 76%, depending on the study design, patient population, and the criteria or definition used for nephrotoxicity \[[@CIT0008], [@CIT0011], [@CIT0012], [@CIT0016], [@CIT0020], [@CIT0021], [@CIT0028]\]. The wide range in nephrotoxicity rates reported in the literature may also be attributed to the lack of standard dosing regimens for colistin across studies. In the RESTORE-IMI 1 study, the dosing of colistin was optimized based on contemporary pharmacokinetic/pharmacodynamic modeling, consistent with current treatment guidelines, to ensure that the given dose was sufficient to achieve efficacy, while balancing concerns about nephrotoxicity \[[@CIT0008], [@CIT0032], [@CIT0033]\]. Colistin dosing was also standardized to ensure that study participants would receive a uniform dose (adjusted for renal function), to support a robust comparison of safety and efficacy against IMI/REL. Despite colistin dose optimization, a more favorable renal safety profile was observed for IMI/REL in this exploratory post hoc analysis, with observed rates of 25% and 31% in the colistin plus IMI treatment group for stage 3 AKI (KDIGO) and failure (RIFLE), respectively. Both KDIGO and RIFLE criteria have demonstrated significant predictive utility for mortality risk in critically ill patients \[[@CIT0034]\]. In our study, the results using both criteria were generally consistent, and these results were comparable to the primary study analysis \[[@CIT0023]\]. This suggests that patient evaluation using either KDIGO or RIFLE criteria should provide reliable indications of nephrotoxicity and that, regardless of definition, incidences of nephrotoxicity were lower in patients treated with IMI/REL compared with those treated with colistin-based therapy.

As in RESTORE-IMI 1, recent clinical studies of other new antibacterial agents compared with colistin-based therapy have suggested that colistin has a higher rate of nephrotoxicity than these newer therapies \[[@CIT0037], [@CIT0038]\]. The consistency of this observation across recent clinical trials is notable for clinicians managing complex infections.

A limitation of this study is the small sample size (n = 45 participants with complete data for the current analysis), which prevented formal statistical between-group comparisons of AE incidence, AKI risk factors, and time to (AKI) event. Although nephrotoxicity was significantly less frequent with IMI/REL than colistin plus IMI, it is notable that nephrotoxicity occurred across a very wide time frame after the initiation of either antibacterial therapy regimen (ie, days 2 to 19 for colistin plus IMI and days 3 to 22 for IMI/REL). The RESTORE-IMI 1 study design did not include a preplanned time-to-event analysis; this may have prevented detection of a discernible pattern of nephrotoxic events related to initiation of therapy (3/29 IMI/REL-treated participants and 9/16 colistin plus IMI--treated participants). In a prospective observational cohort study, Dalfino et al. observed a median time to onset of AKI (by Acute Kidney Injury Network criteria) of 5 days, with an interquartile range of 3 to 14 days, in 31 colistin-treated participants with severe sepsis or shock \[[@CIT0030]\]. In a larger retrospective cohort study, including 64 colistin-treated participants who developed nephrotoxicity, the mean time to peak serum creatinine for colistin-treated participants was 6.5 days \[[@CIT0028]\]. Future observational studies with larger sample sizes can provide more insight into the timing and patterns of nephrotoxic events associated with colistin and other potentially nephrotoxic antibacterial agents.

For patients with renal impairment and/or those in whom potential de novo nephrotoxicity might make medical management of these challenging infections even more complex, it is appropriate to choose antibacterial agents to minimize renal toxicity. In adult patients with serious, imipenem-nonsusceptible gram-negative bacterial infections, IMI/REL has a more favorable renal safety profile than colistin-based therapy, regardless of the assessment criteria applied.

Supplementary Data {#s7}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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